Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis

被引:6
作者
Kwatra, Shawn G. [1 ]
Rodriguez, Danielle [2 ]
Dias-Barbosa, Carla [3 ]
Budhiarso, Ismail [2 ]
Fofana, Fatoumata [4 ]
Vernon, Margaret [5 ]
Gabriel, Sylvie [6 ]
Piketty, Christophe [6 ]
Puelles, Jorge [6 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD USA
[2] Evidera, 615 2nd Ave Ste 500, Seattle, WA 98104 USA
[3] Evidera, Ivry, France
[4] Evidera, Bennekom, Netherlands
[5] Evidera, Bethesda, MD USA
[6] Galderma, La Tour De Peilz, Switzerland
关键词
Itch; Nodular prurigo; Outcome measurement; Patients; Pruritus; Qualitative research; Quality of life; RELIABILITY; VALIDITY; MODERATE; INSTRUMENT; BURDEN; LIFE;
D O I
10.1007/s13555-023-00999-9
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionValidated patient report tools for quantifying patient experiences of itch in prurigo nodularis (PN) are limited. This study aimed to evaluate the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item patient-reported outcome (PRO) measure for assessing itch severity in PN.MethodsContent validity of the PP NRS was evaluated through qualitative interviews with adults with PN. The PP NRS was then psychometrically evaluated using data from a placebo-controlled trial of nemolizumab in adults with PN, during which patients completed the PP NRS daily. Meaningful within-patient change was estimated from the qualitative interviews and by anchor- and distribution-based analyses of trial data.ResultsThe interview participants (N = 21) all understood the PP NRS and reported itch as their worst symptom overall. The PP NRS showed good test-retest reliability and demonstrated convergent validity and known-groups validity. PP NRS scores improved more in patients classified as "improved" on other clinical outcome measures than in those classified as "worsened/unchanged". Triangulation of the different estimates identified a 2- to 5-point decrease in PP NRS score as a meaningful within-patient change threshold.ConclusionThe PP NRS is a content-valid and reliable PRO measure for quantifying itch severity in adults with PN in clinical trials.Trial Registration NumberNCT03181503. Prurigo nodularis is a skin disease where the skin becomes inflamed and very itchy. Itching and scratching can ruin the lives of people with prurigo nodularis. For doctors to know how well treatments for prurigo nodularis are working, they need to be able measure how bad their patients' itching is. Here we tested whether a tool called the peak pruritus numeric rating scale (PP NRS) can be used to reliably measure itching in patients with prurigo nodularis. The PP NRS asks patients to rate their itch "at the worst moment during the previous 24 h" on a scale from 0 ("no itch") to 10 ("worst itch imaginable"). We interviewed 21 patients with prurigo nodularis. Overall, itch was their worst symptom. They were able to use the PP NRS with few or no problems. To further explore whether the PP NRS can be used by patients with prurigo nodularis, we also obtained data from a clinical study. In this clinical study, patients with prurigo nodularis received a drug that might one day be used to treat their disease. They completed the PP NRS daily during the time they received the drug. When we analyzed the data from the clinical study, we found that the PP NRS has the properties a tool like this needs to be useful. We also concluded that a decrease of 2-5 points on the PP NRS scale would be a meaningful improvement in itching for patients with prurigo nodularis.
引用
收藏
页码:2403 / 2416
页数:14
相关论文
共 37 条
[1]   Clinical characteristics and disease burden in prurigo nodularis [J].
Aggarwal, P. ;
Choi, J. ;
Sutaria, N. ;
Roh, Y. S. ;
Wongvibulsin, S. ;
Williams, K. A. ;
Huang, A. H. ;
Boozalis, E. ;
Le, T. ;
Chavda, R. ;
Gabriel, S. ;
Kwatra, S. G. .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2021, 46 (07) :1277-1284
[2]  
Chanis R, 2020, VIRTUAL ISPOR EUROPE
[3]  
Cohen J. W, 1988, STAT POWER ANAL BEHA
[4]   Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial [J].
Eichenfield, Lawrence F. ;
Flohr, Carsten ;
Sidbury, Robert ;
Siegfried, Elaine ;
Szalai, Zsuzsanna ;
Galus, Ryszard ;
Yao, Zhirong ;
Takahashi, Hidetoshi ;
Barbarot, Sebastien ;
Feeney, Claire ;
Zhang, Fan ;
DiBonaventura, Marco ;
Rojo, Ricardo ;
Valdez, Hernan ;
Chan, Gary .
JAMA DERMATOLOGY, 2021, 157 (10) :1165-1173
[5]  
EMA, 2022, DUP EPAR PROD INF AN
[6]  
FDA, 2009, GUID IND PATI REP OU
[7]  
FDA, 2021, DUPIXENT DUP INJ SUB
[8]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[9]   The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review [J].
Gwillim, E. C. ;
Janmohamed, S. R. ;
Yousaf, M. ;
Patel, K. R. ;
Silverberg, J. I. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) :E815-E817
[10]   Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis [J].
Huang, A. H. ;
Canner, J. K. ;
Williams, K. A. ;
Grossberg, A. L. ;
Kwatra, M. M. ;
Kwatra, S. G. .
BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) :182-184